On Tuesday, Shares of Twitter, Inc. (NYSE:TWTR), gained 0.59% to $37.50.
Google has regained the ability to use real-time tweets in its search results ending a four year absence of content from Twitter being shown in the search engine.
The new agreement between the two companies will see tweets appear for users of US users searching from either the Google app on iOS or Android, or from Google’s mobile search page.
“The desktop web version is coming shortly, and we have plans to bring this feature to more countries in the coming months,” Twitter said in a blog post.
Twitter, Inc. operates as a global platform for public self-expression and conversation in real time. It offers various products and services for users, counting Twitter that allows users to create, distribute, and discover content; and Vine and video, a mobile application that enables users to create and distribute short looping videos.
Shares of Tyco International Ltd. (NYSE:TYC), inclined 1.11% to $40.19, during its last trading session.
Tyco International, Chief Executive Officer George Oliver will speak at the 31st annual Bernstein Planned Decisions Conference in New York on Friday, May 29, 2015, at 8:00 a.m. ET.
Tyco International Ltd. designs, sells, installs, and services security, fire detection, suppression, and life safety products worldwide. It operates in three segments: North America Installation & Services, Rest of World Installation & Services, and Global Products.
At the end of Tuesday’s trade, Shares of MasterCard Incorporated (NYSE:MA), gained 0.77% to $93.80.
InterContinental Hotels Group (IHG), one of the world’s leading hotel companies, has partnered with MasterCard to give away 60 first prizes of one-night stays at InterContinental® Hotels & Resorts, Crowne Plaza® Hotels & Resorts, Hotel Indigo® Hotels, Holiday Inn® Hotels, Holiday Inn Express® Hotels, Staybridge Suites® Hotels, Candlewood Suites® Hotels and EVEN® Hotels during the “One More Day” summer sweepstakes. From May 31 through July 30, 2015, members of the world’s first and largest hotel loyalty program, IHG® Rewards Club, who stay at an IHG hotel2 and pay using their MasterCard, will be entered for a chance to win “One More Day” of vacation via a one-night stay at an IHG hotel.
MasterCard Incorporated, a technology company, provides transaction processing and other payment-related products and services in the United States and internationally. The company facilitates the processing of payment transactions, counting authorization, clearing, and settlement, in addition to delivers related products and services.
Finally, Celgene Corporation (NASDAQ:CELG), ended its last trade with 0.41% gain, and closed at $116.85.
Celgene Corporation, declared that a post-hoc subgroup analysis of a double-blind, placebo-controlled, randomized, multicenter phase II trial of GED-0301 (mongersen) in patients with active Crohn’s disease was presented at Digestive Disease Week (DDW) in Washington, D.C.
The primary findings of the phase II trial, which enrolled 166 adult patients with active Crohn’s disease, defined as Crohn’s Disease Activity Index (CDAI) scores >220 to ≤400, were published in the March 19, 2015 issue of The New England Journal of Medicine. Patients in the trial were treated for two weeks with either placebo or one of three doses of GED-0301 (10 mg, 40 mg or 160 mg tablets, once daily) and then followed for an additional 10 weeks. The presentation at DDW retrospectively examined certain subgroups of patients in the trial.
In the subgroup analysis, patients were grouped by disease duration (<5 years vs. ≥5 years), baseline CDAI score (<260 vs. ≥260) and baseline levels of the C-reactive protein (CRP) inflammatory marker (<3 mg/L vs. ≥3 mg/L). Patients in these subgroups were then analyzed for clinical remission (a CDAI score <150) and clinical response (CDAI score reduction ≥100 points from baseline) at weeks 2 and 4. Clinical remission rates for patients treated with GED-0301 160 mg were similar regardless of disease duration or baseline CDAI or CRP levels and were higher than those for patients on placebo (remission rates ranged from 62.5 percent to 75 percent for GED-0301 160 mg vs. 5 percent to 24 percent for placebo). These findings provide a rationale for continued evaluation of the 160 mg dose in the phase III program.
For patients with a disease duration of at least five years (mean of 15.4 years), 62.5 percent (15/24) of those treated with GED-0301 160 mg were in clinical remission at week 2, contrast with 15.4 percent (4/26) of those treated with placebo. Similar results were observed at week 4 (66.7 percent [16/24] vs. 15.4 percent [4/26], respectively). Clinical response rate was 70.8 percent (17/24) with GED-0301 160 mg, contrast with 19.2 percent (5/26) with placebo, at week 2 and 79.2 percent (19/24) as compared to 26.9 percent (7/26), respectively, at week 4.
For patients with baseline CDAI of at least 260 (median of 303), 62.5 percent (10/16) of those treated with GED-0301 160 mg were in clinical remission at week 2, contrast with 13.6 percent (3/22) for placebo and 75.0 percent (12/16) as compared to 4.5 percent (1/22), respectively, at week 4. Clinical response rate was 87.5 percent (14/16) with GED-0301 160 mg as compared to 22.7 percent (5/22) for placebo at week 2 and 87.5 percent (14/16) as compared to 22.7 percent (5/22), respectively, at week 4.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, in addition to acute myeloid leukemia (AML).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
